ライフサイエンスコーパス: SCT

1 SCT continues to serve as a platform of "operational cur

2 SCT images were generated from MRI scans using a commerc

3 SCT is not associated with reduced fitness in this longi

4 SCT results were highly concordant with available clinic

5 SCT status also is not an independent risk factor for de

6 those with (5.72%) vs those without (6.01%) SCT (mean HbA1c difference, -0.29%; 95% CI, -0.35% to -0

7 A total of 2233 individuals (239 of 1247 SCT carriers [19.2%] vs 1994 of 14,722 noncarriers [13.5

8 ienced decline in eGFR, and 1322 (154 of 485 SCT carriers [31.8%] vs 1168 of 5947 noncarriers [19.6%]

9 , we prospectively collected plasma from 492 SCT patients with newly diagnosed acute GVHD and randoml

10 ) experienced incident CKD, 1719 (150 of 665 SCT carriers [22.6%] vs 1569 of 8249 noncarriers [19.0%]

11 ncarriers [13.5%]) had CKD, 1298 (140 of 675 SCT carriers [20.7%] vs 1158 of 8481 noncarriers [13.7%]

12 ric patients who were scheduled to undergo a SCT were eligible for the study, with 315 patients compl

13 d spleen size were assessed before and after SCT and compared with hematologic response criteria and

14 underwent (18)F-FDG PET/CT before and after SCT.

15 PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [C

16 at immune suppression with cyclosporin after SCT limits T-helper cell (Th) 1 differentiation and inte

17 The patients died 96 and 129 days after SCT, respectively, one of them after receiving additiona

18 context of intense inflammation early after SCT.

19 antigens by donor dendritic cells late after SCT that is mandatory for the establishment of effective

20 egy to prevent morbidity and mortality after SCT and has been increasingly studied in the last 15 yea

21 IMN occurs rarely in patients after SCT.

22 D8(+) Tc17 population develops rapidly after SCT but fails to maintain lineage fidelity such that the

23 subjects stabilized for several weeks after SCT, but finally deteriorated.

24 cognitive losses during the first year after SCT and to maximize potential recovery.

25 sses experienced during the first year after SCT, demonstrating stability in their functioning, but a

26 In B-cell precursor ALL, SCT also benefitted patients with focal IKZF1 gene delet

27 nkfurt-Muenster (BFM) study group trial: ALL-SCT-BFM 2003 (Allogeneic Stem Cell Transplantation in Ch

28 Allo-SCT has a high morbidity and is precluded for many patie

29 allo-SCT led to a significant reduction in the size of the HI

30 ty-nine patients who had relapsed after allo-SCT for AML (n = 24) or MDS (n = 5) were treated with se

31 chronic HIV infection before and after allo-SCT to measure the size of the HIV-1 reservoir and chara

32 Early after allo-SCT, CD8+ stem cell memory T cells targeting minor histo

33 in the skin of patients with GVHD after allo-SCT.

34 therapy for newly diagnosed cGVHD after allo-SCT.

35 me is frequently dysregulated following allo-SCT and that this dysbiosis can predispose to adverse cl

36 manipulate the graft content to improve allo-SCT outcome.

37 ractions with the host immune system in allo-SCT and posttransplant complications.

38 directly promotes their development in allo-SCT.

39 (allo-SCT), several subsequent cases of allo-SCT in HIV-1 positive individuals have failed to cure HI

40 investigated to improve the outcomes of allo-SCT patients in regard to acute intestinal GVHD.

41 ional cycles of blinatumomab instead of allo-SCT.

42 d allogeneic stem cell transplantation (allo-SCT) as consolidation for blinatumomab and 2 who receive

43 r allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia

44 ematopoietic stem cell transplantation (allo-SCT) is potentially curative for a number of hematologic

45 ematopoietic stem cell transplantation (allo-SCT) offers cure for a variety of conditions, in particu

46 g allogeneic stem cell transplantation (allo-SCT), several subsequent cases of allo-SCT in HIV-1 posi

47 r allogeneic stem cell transplantation (allo-SCT).

48 r allogeneic stem cell transplantation (allo-SCT).

49 t allogeneic stem cell transplantation (allo-SCT).

50 ve antiretroviral therapy who underwent allo-SCT for treatment of acute lymphoblastic leukemia.

51 Allogeneic SCT in first remission has potent antileukemic efficacy

52 Allogeneic SCT led to a significantly prolonged RFS in patients wit

53 Allogeneic SCT offers a chance for cure in patients with high-risk

54 A total of 104 patients (84 allogeneic SCT recipients and 20 patients with leukemia) received i

55 oring of treatment response after allogeneic SCT for myelofibrosis.

56 ts whose disease progressed after allogeneic SCT.

57 g the CMV reactivation risk after allogeneic SCT.

58 tet(low) and tet(high) CTLs after allogeneic SCT.

59 nostic factors of survival in all allogeneic SCT recipients admitted to the ICU between 2002 and 2013

60 ients were intended to receive an allogeneic SCT if an HLA-identical sibling donor was available.

61 patients with acute leukemia and allogeneic SCT recipients.

62 om 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT.

63 Before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and b

64 patients with an available donor, allogeneic SCT may also be considered.

65 se (high risk) were scheduled for allogeneic SCT after reinduction chemotherapy.

66 s with NPM1(mut) AML eligible for allogeneic SCT in a donor versus no-donor analysis.

67 For allogeneic SCT, the 2-year PFS estimate was 68% (95% confidence int

68 ify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy.

69 Early mortality of allogeneic SCT recipients admitted to the ICU is especially influen

70 re (p = 0.007) and not undergoing allogeneic SCT (p = 0.007) was found to significantly predict poor

71 counts among patients undergoing allogeneic SCT or chemotherapy and because platelet transfusions ma

72 Of 349 patients who underwent allogeneic SCT during the study period, 92 patients (26%) were admi

73 ent (long-term disease control vs allogeneic SCT).

74 Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvag

75 , the relative risk of death after allogenic SCT vs those treated with nontransplant modalities was 5

76 high-risk PMF clearly benefit from allogenic SCT.

77 ears old at diagnosis who received allogenic SCT (n = 190) or conventional therapies (n = 248).

78 nent strategy composed of STD, ASP, ENV, and SCT was the most effective intervention (rate ratio [RR]

79 ssociated with improved PFS, but not OS, and SCT was not associated with improved OS among patients a

80 bursts of beta activity in both the RTT and SCT.

81 ived SCT in first remission were censored at SCT time, 2-year RFS was 53.3% (95% CI, 39% to 66%) in t

82 transplantation (SCT) in first remission at SCT time.

83 h autologous stem cell transplantation (auto-SCT) have shown promising results but have never been te

84 naplastic large cell lymphoma), upfront auto-SCT was associated with a superior OS (HR, 0.58; P = .00

85 compared with patients treated without auto-SCT.

86 For early relapsed ALCL autologous SCT was not effective.

87 T performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success.

88 had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions.

89 d 102 underwent FDG PET/CT before autologous SCT.

90 roup consolidated per protocol by autologous SCT, EFS and OS of 23 patients were 30% +/- 10% and 78%

91 For autologous SCT, the 2-year PFS was 72% (95% CI: 64%, 82%) in patien

92 t of ulcerative oral mucositis in autologous SCT (autoSCT) recipients.

93 Before termination of autologous SCT, EFS rates of patients in the very-high- (n = 17), h

94 lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010.

95 ion (SCT) if they had a donor, or autologous SCT if in MMolR and no donor.

96 e donor received consolidation or autologous SCT.

97 tine (intermediate risk) received autologous SCT after carmustine-etoposide-cytarabine-melphalan.

98 erapy but not in those undergoing autologous SCTs.

99 Performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic

100 ed more than three treatment regimens before SCT.

101 To evaluate the association between SCT and HbA1c for given levels of fasting or 2-hour gluc

102 sess the strength of the association between SCT and malaria, using current data for both SCT and mal

103 veal a significant difference in RFS between SCT and no-SCT cohorts.

104 In the ALL-BFM-SCT 2003 trial, MRD was assessed in the bone marrow at d

105 SCT and malaria, using current data for both SCT and malaria infections.

106 DSP-Zn-NP administered by SCT injection provided detectable DSP levels in both the

107 eralized junctional epidermolysis bullosa by SCT is a last-ditch attempt still lacking proof of effic

108 The HbA1c difference by SCT was greater at higher fasting (P = .02 for interacti

109 a key modulator of cAMP responses induced by SCT stimulation of SCTR.

110 hological process was greatly neutralized by SCT injection of Sunb-malate MS.

111 ity/mortality after hematopoietic stem cell (SCT) or solid organ (SOT) transplant.

112 dysregulated in patients undergoing clinical SCT and is present at very high levels in the plasma of

113 In this cohort, SCT strongly associated with risk of progression to ESRD

114 For the major isomer 5a, the computed SCT rate constant for bond shifting at 80 K is 0.16 s(-1

115 brentuximab vedotin other than consolidative SCT.

116 in sustained remission without consolidative SCT or any new anticancer therapy.

117 lonization methods (DCL), or source control (SCT), simultaneously.

118 creases from 1:13 at CVT level to 1:2 at CVT+SCT level for room temperature.

119 eory with multidimensional tunneling (MS-CVT/SCT) at the high-pressure limit.

120 DI-SCT is a fast and safe tool to identify simulated sleep

121 g drug-induced sleep computed tomography (DI-SCT) in patients with OSA.

122 utations in MYH3 underlie autosomal dominant SCT, identify a postnatal role for embryonic myosin and

123 resetting drift-diffusion model (DDM) during SCT.

124 sequentially and that are resetting in each SCT tap.

125 arge cholangiocytes with knocked down either SCT or SR by short hairpin RNAs show reduced EV secretio

126 although, to date, efforts toward employing SCT in diverse applications have been limited, and progr

127 -Neu5Ac in the alpha-2,6-linkage (alpha2,6-F-SCT) has a similar binding avidity as its parent glycofo

128 Sunb-malate MS following SCT injection more effectively suppressed the suture-ind

129 ssion levels of these two proteins following SCT, we showed that in vivo eIF5A1 up-regulation and dow

130 ntional high-risk factor were candidates for SCT in first complete remission.

131 itially normal weight gain, the decision for SCT from haploidentical bone marrow or peripheral blood

132 Intergrader ICCs were greater for SCT (0.959-0.980) than for TCT (0.928-0.963) and VCT (0.

133 Intergrader CRs were lower for SCT (41.40-62.31) than for TCT (61.13-74.24) or VCT (72.

134 ere, a simple solution-processing method for SCT that allows its conductivity and optical properties

135 ystem to kill CLL cells without the need for SCT.

136 his study further supports the potential for SCT testing to become a diagnostic prenatal test.

137 The discovery of new uses for SCT would therefore bring both economic and environmenta

138 uring LPS stimulation, and EVs isolated from SCT or SR knocked down cholangiocytes fail to induce inf

139 The median time from SCT to IMN was 7 months.

140 Furthermore, SCT DSP-Zn-NP significantly reduced microglia cell densi

141 However, SCT calculations show that a narrower barrier and smalle

142 However, SCT was associated with longer RFS in patients with post

143 ed risk for exertion-related sudden death in SCT carriers is unlikely related to fitness.

144 tion of the intervals produced by monkeys in SCT is replicated by the model.

145 tion of the intervals produced by monkeys in SCT.

146 racker CM-H2TMRosa, is higher in CTB than in SCT in culture and living explants.

147 glycolysis, are both greater in CTB than in SCT in vitro (CTB: 96 +/- 16 vs SCT: 46 +/- 14 pmol O2 x

148 Moreover, differentiation into SCT leads to metabolic suppression.

149 ion chemotherapy and radiotherapy after last SCT.

150 Because of migration, SCT is becoming common outside tropical countries: It is

151 Nevertheless, SCT still remains an option for accelerated/blastic-phas

152 ificant difference in RFS between SCT and no-SCT cohorts.

153 ce is associated with an increase by 4.3% of SCT carriers.

154 ge is associated with an increase by 5.5% of SCT carriers.

155 iation of AT1aR with SCTR reduced ability of SCT to stimulate cyclic adenosine monophosphate (cAMP),

156 R of CLARA over HDAC before or in absence of SCT was 0.65 (95% CI, 0.43 to 0.98; P = .041).

157 A1c stratified by the presence or absence of SCT was the primary outcome measure.

158 We evaluated the association of SCT status with cross-sectional and longitudinal changes

159 nalysis, there was neither an association of SCT status with longitudinal changes in fitness nor an a

160 quations (GEE) to examine the association of SCT with HbA1c levels, controlling for fasting or 2-hour

161 eous in nature, the molecular composition of SCT has the potential to serve as a diverse and tunable

162 olicy implications for genetic counseling of SCT carriers.

163 To handle the confounding effect of SCT that could occur in patients with late donor identif

164 tructure of the internally timed elements of SCT.SIGNIFICANCE STATEMENT The present study used behavi

165 ividuals have an autosomal recessive form of SCT and are homozygous or compound heterozygous for nons

166 tologous SCT indicates a lower likelihood of SCT success.

167 These results highlight the potential of SCT as a feedstock material for electronic applications

168 Americans in these cohorts, the presence of SCT was associated with an increased risk of CKD, declin

169 Overall, the prevalence of SCT was 6.8% (136/1995) in CARDIA, and over the course o

170 We attempt to define the role of SCT in the era of targeted therapies and discuss questio

171 Further investigations into the roles of SCT and novel agents are needed.

172 nalysis, RT or low hemoglobin at the time of SCT predicted shorter OS.

173 When ENV was added to STD+ASP or SCT was added to STD+ENV, there was a significant reduct

174 at low catechol loadings on solid particles (SCT).

175 I and age on cognitive outcomes in pediatric SCT survivors.

176 receiving or were candidates to receive post-SCT cell-based therapies were not included in this analy

177 Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled p

178 rall, 110 patients (55 in each arm) received SCT in first remission.

179 itivity analysis, when patients who received SCT in first remission were censored at SCT time, 2-year

180 ve chart review of the Mayo Clinic Rochester SCT database between January 1997 and August 2012.

181 rican Americans (1248 participants with SCT [SCT carriers] and 14,727 participants without SCT [nonca

182 Angiotensin (ANGII) and secretin (SCT) share overlapping, interdependent osmoregulatory fu

183 gastrointestinal peptide hormone, secretin (SCT) that binds to secretin receptor (SR), is a key medi

184 of the eye in animals that received a single SCT injection of DSP-Zn-NP as compared to animals that r

185 ohort, in which all patients received single SCT and 21.6 Gy without a boost.

186 were randomly assigned or assigned to single SCT and received boost radiotherapy (n = 74) were 16.3%

187 easured to the border of the choroid stroma (SCT) than the vascular lumen (VCT) or sclera (TCT).

188 Subconjunctival (SCT) injection is a less invasive option that is a commo

189 Subconjunctival (SCT) injection of Sunb-malate MS provided a prolonged oc

190 scleral diffusion following subconjunctival (SCT) injection in comparison to its sunitinib free base

191 (VCT) that differentiates into superimposed SCT.

192 ges, differentiation of syncytiotrophoblast (SCT), a cell type critical for hormone production and se

193 The syncytiotrophoblast (SCT) at the maternal-fetal interface has been presumed t

194 m and differentiated to syncytiotrophoblast (SCT) and extravillous trophoblast (EVT) was a two-dimens

195 Spondylocarpotarsal synostosis (SCT) is a skeletal disorder characterized by progressive

196 Steam-cracker tar (SCT) is a by-product of ethylene production that is in m

197 forming a synchronization-continuation task (SCT) and a serial reaction-time task (RTT), where the an

198 using the synchronization-continuation task (SCT), where subjects initially tap in synchrony with an

199 a synchronization-continuation tapping task (SCT).

200 inically validated standard comparator test (SCT), the GP5+/6+ enzyme immunoassay (EIA).

201 fitness is not known, despite concerns that SCT is associated with exertion-related sudden death.

202 We have learned that SCT and cardiac surgery is not a benign combination.

203 These findings suggest that SCT may be associated with the higher risk of kidney dis

204 in Ph+ ALL adult patients and suggests that SCT in first CR is still a good option for Ph+ ALL adult

205 6 and HPV18/45 between the Xpert HPV and the SCT was also analyzed.

206 lic rate of the placenta is dominated by the SCT contribution.

207 During the SCT, beta was higher during the internally driven contin

208 rebound during the continuation phase of the SCT suggests that the corticostriatal circuit is involve

209 r (CIN2+) and CIN3+ relative to those of the SCT were assessed as were the inter- and intralaboratory

210 nitial burst of beta at the beginning of the SCT, similar to the RTT, followed by a decrease in beta

211 t laser annealing can be used to process the SCT films and directly pattern transparent heaters on an

212 tabolic rate of CTB is much greater than the SCT.

213 g LPS stimulation, and demonstrates that the SCT/SR axis may be important for this event.

214 sustained release of Sunb-malate through the SCT injection of Sunb-malate MS mitigated the proliferat

215 the undifferentiated CTB, in contrast to the SCT, is highly metabolically active, has a high level of

216 The SCTs bind such that the triazolinone ring is inserted de

217 the thiazolium ring is cleaved, but when the SCTs bind, ThDP is modified to thiamine 2-thiazolone dip

218 le heaters, even without optimization, these SCT devices show competitive performance compared to est

219 Subfoveal choroidal thickness (SCT) was measured using the SDOCT.

220 hickness (VCT), stromal choroidal thickness (SCT), and total choroidal thickness (TCT), respectively.

221 choroid stroma (stromal choroidal thickness, SCT), or inner scleral border (total choroidal thickness

222 y factor significantly interacting with this SCT effect.

223 Exome sequence analysis of three SCT patients negative for FLNB mutations identified an a

224 bolic activity during CTB differentiation to SCT is prevented with a p38 MAPK signaling inhibitor and

225 rsus-host disease and an initial response to SCT predicted longer OS.

226 The association between sickle cell trait (SCT) and chronic kidney disease (CKD) is uncertain.

227 lobin variants, including sickle cell trait (SCT) and hemoglobin C trait, have a role in kidney disea

228 differ between those with sickle cell trait (SCT) and those without it.

229 The contribution of sickle cell trait (SCT) to racial disparities in cardiopulmonary fitness is

230 nagement of patients with sickle cell trait (SCT) undergoing cardiac surgery, since it is recognized

231 eterozygous state, called sickle cell trait (SCT).

232 14 to 28 days after spinal cord transection (SCT) in rats.

233 induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patients with previously unt

234 ceived a consolidative stem cell transplant (SCT) with median PFS not reached.

235 e following autologous stem cell transplant (SCT), multiple treatment options are available, includin

236 undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor overall survival.

237 tandem autologous stem-cell transplantation (SCT) after induction chemotherapy.

238 ous hematopoietic stem cell transplantation (SCT) and vinblastine monotherapy.

239 ase have expanded stem cell transplantation (SCT) availability for chronic lymphocytic leukemia (CLL)

240 after allogeneic stem cell transplantation (SCT) for myelofibrosis.

241 Allogeneic stem cell transplantation (SCT) has been proposed as a therapeutic approach, yet wi

242 le for allogeneic stem cell transplantation (SCT) if they had a donor, or autologous SCT if in MMolR

243 after allogeneic stem cell transplantation (SCT) in both mice and humans.

244 ceived allogeneic stem cell transplantation (SCT) in first remission at SCT time.

245 ole of allogeneic stem cell transplantation (SCT) in patients treated in the GRAALL-2003 and GRAALL-2

246 Allogeneic stem-cell transplantation (SCT) induces long-term remission in a fraction of patien

247 Allogeneic stem cell transplantation (SCT) is a unique procedure, primarily in patients with h

248 after allogeneic stem cell transplantation (SCT) is hindered by adverse events and drug-drug interac

249 eic hematopoietic stem cell transplantation (SCT) is the only curative option for patients with prima

250 ion of allogeneic stem cell transplantation (SCT) recipients to the intensive care unit (ICU) remains

251 or for allogeneic stem-cell transplantation (SCT) were eligible.

252 lowing allogeneic stem cell transplantation (SCT), the mechanisms of which are unclear.

253 rgoing allogeneic stem cell transplantation (SCT), using the composite end point of graft-versus-host

254 ard to allogeneic stem-cell transplantation (SCT), we compared the clinical course of patients with N

255 ndergo allogeneic stem cell transplantation (SCT).

256 sed on allogeneic stem cell transplantation (SCT).

257 after allogeneic stem cell transplantation (SCT).

258 neic haemopoietic stem-cell transplantation (SCT).

259 after allogeneic stem cell transplantation (SCT).

260 after allogeneic stem cell transplantation (SCT).

261 receiving allogeneic stem cell transplants (SCTs) or chemotherapy but not in those undergoing autolo

262 of the sulfonylamino-carbonyl-triazolinone (SCT) herbicide families, revealing the structural basis

263 protocol for single circulating trophoblast (SCT) testing using positive selection by magnetic-activa

264 multidimensional small-curvature tunneling (SCT) computations indicate that, under cryogenic conditi

265 ) as well as with small curvature tunneling (SCT) contributions, via direct dynamics.

266 CVT) inclusive of small curvature tunneling (SCT) reveals the influential role of quantum mechanical

267 Of the 3305 patients who underwent SCT, 12 patients (0.36%) had IMN.

268 ful applications, the production of unwanted SCT leads to the need for its costly disposal or burning

269 showed greater reliability for averaged VCT, SCT, or TCT measurements than at individual locations.

270 CTB than in SCT in vitro (CTB: 96 +/- 16 vs SCT: 46 +/- 14 pmol O2 x min(-1) x 100 ng DNA(-1), p < 0

271 DNA(-1), p < 0.001) and (CTB: 43 +/- 6.7 vs SCT 1.4 +/- 1.0 mpH x min(-1) x 100 ng DNA(-1), p < 0.00

272 ronment, catechol degradation decreased when SCT was <1 mug/mg but increased when SCT was >1 mug/mg.

273 ed when SCT was <1 mug/mg but increased when SCT was >1 mug/mg.

274 ent osmoregulatory functions in brain, where SCT peptide/receptor function is required for ANGII acti

275 valuated 9909 self-reported blacks (739 with SCT and 243 with hemoglobin C trait).

276 ] years; 2835 women [61.3%]; 367 [7.9%] with SCT) with 9062 concurrent measures of fasting glucose an

277 Sex is not associated with SCT.

278 ophasic course and temporal association with SCT and (2) a paraneoplastic phenomenon, supported by fr

279 he plasma of patients with IPS compared with SCT recipients without complications.

280 th individuals without SCT, individuals with SCT had a hazard ratio for ESRD of 2.03 (95% confidence

281 Individuals with SCT had an increased risk of CKD (odds ratio [OR], 1.57

282 ccurred in 40 of 739 (5.4%) individuals with SCT, six of 243 (2.5%) individuals with hemoglobin C tra

283 ed African Americans (1248 participants with SCT [SCT carriers] and 14,727 participants without SCT [

284 per 1000 person-years for participants with SCT and 4.0 per 1000 person-years for noncarriers.

285 s in 572 observations from participants with SCT and 6877 observations from participants without SCT;

286 well-established cohorts, participants with SCT had lower levels of HbA1c at any given concentration

287 participants without SCT, participants with SCT had similar baseline measures of fitness in cross-se

288 significantly lower among participants with SCT when defined using HbA1c values (29.2% vs 48.6% for

289 stimate past glycemia in black patients with SCT and may require further evaluation.

290 s the danger of complacency in patients with SCT, offering a learning opportunity for the cardiothora

291 ucose and HbA1c concentration for those with SCT (mean, 5.35%) vs those without SCT (mean, 5.65%) for

292 A 49-year-old woman with SCT (HbS 38%) with postpartum cardiomyopathy underwent c

293 ve excellent long-term outcomes even without SCT.

294 Compared with individuals without SCT, individuals with SCT had a hazard ratio for ESRD of

295 CT carriers] and 14,727 participants without SCT [noncarriers]).

296 Participants without SCT data, those without any concurrent HbA1c and glucose

297 Compared with participants without SCT, participants with SCT had similar baseline measures

298 r glucose compared with participants without SCT.

299 6877 observations from participants without SCT; P<.001 for both comparisons).

300 hose with SCT (mean, 5.35%) vs those without SCT (mean, 5.65%) for a mean HbA1c difference of -0.30%

301 e adjusted on the time-dependent treatment x SCT interaction term.

302 of a multivariable Cox-adjusted treatment x SCT interaction, the HR of CLARA over HDAC before or in